Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Publication details: 2018; ISSN:- 0028-4793
- *Anti-Obesity Agents/tu [Therapeutic Use]
- *Benzazepines/tu [Therapeutic Use]
- *Cardiovascular Diseases/co [Complications]
- *Hypoglycemia/ci [Chemically Induced]
- *Obesity/dt [Drug Therapy]
- *Overweight/dt [Drug Therapy]
- *Weight Loss/de [Drug Effects]
- Aged
- Anti-Obesity Agents/ae [Adverse Effects]
- Aortic Valve Insufficiency/ci [Chemically Induced]
- Benzazepines/ae [Adverse Effects]
- Cardiovascular Diseases/ci [Chemically Induced]
- Cardiovascular Diseases/ep [Epidemiology]
- Diabetes Mellitus, Type 2/co [Complications]
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Hypertension, Pulmonary/ci [Chemically Induced]
- Male
- Middle Aged
- Obesity/co [Complications]
- Overweight/co [Complications]
- Risk Factors
- MedStar Heart & Vascular Institute
- Journal Article
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | 30145941 | Available | 30145941 |
English